Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study is to investigate safety and feasibility of a combination therapy of a tumor
infiltrating lymphocytes (TIL) transfer with anti-programmed cell death protein (PD)-1
therapy in patients with metastatic melanoma that failed immunotherapy.Tumor-infiltrating
lymphocytes will be expanded from resected melanoma samples from the patient and expanded
TILs will be transferred to the patient after non-myeloablative chemotherapy with
cyclophosphamide and fludarabine. TIL transfer will be combined with low dose Interleukin
(IL)-2 and nivolumab anti-PD-1 treatment.
The study uses a personalized Investigational Medicinal Product (IMP), i.e. TIL product and
in combination with IL-2 treatment and nivolumab.